TAU Annual Report 2022

We are glad to present the 2022 Annual Report of TAU here. Since TAU was launched, TAU articles have been cited 10,058 times by articles indexed in Web of Science Core Collection. TAU continues to publish cutting-edge research covering the whole spectrum of andrology and urology.

Read More>>

50 Years Anniversary of The Modern Artificial Urinary Sphincter (Ongoing)

This special series on “50 years anniversary of the modern artificial urinary sphincter” is edited by Dr. Eric Chung from Princess Alexandra Hospital (Brisbane, QLD), Australia.

Read More>>

Upper Tract Urothelial Cancer (Ongoing)

The series on “Upper Tract Urothelial Cancer” is edited by Dr. Ram A. Pathak from Mayo Clinic-Jacksonville (USA) and Dr. Ashok K. Hemal from Atrium Health Wake Forest Baptist (USA).

Read More>>

Interviews with Outstanding Authors (2022)

In 2022, many TAU authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspective and insightful view as authors.

Read More>>

Complex Penile Prosthesis Surgery (Ongoing)

The series on “Complex Penile Prosthesis Surgery” is edited by Prof. Martin Gross from Dartmouth Health Medical Center (USA), Prof. Jay Simhan from Fox Chase Cancer Center (USA), and Prof. David Barham from University of California (USA).

Read More>>

New Impact Factor for Translational Andrology and Urology: 2.479

We are pleased to announce that the Translational Andrology and Urology (TAU) has attained its latest impact factor update for the 2021 citation year: 2.479.

Here, we would like to extend our heartfelt gratitude to all our Editorial Team Members, Guest Editors, authors, and reviewers for their valuable contributions.

Read More>>

Reviewer of the Month (2022)

In 2022, TAU reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Read More>>

Translational Andrology and Urology (TAU) is now a member of Committee on Publication Ethics (COPE)

Starting from July 2021, AME Publishing Company is formally recognized a publisher member of Committee on Publication Ethics (COPE) and over 60 AME-published journals become a member of Committee on Publication Ethics (COPE), as part of AME’s commitment to best practice in scholarly publishing. Translational Andrology and Urology (TAU) is among the list of COPE membership.

Read More>>

Surgical Management of Stress Urinary Incontinence in Men (ongoing)

This special series will focus on Surgical Management of Stress Urinary Incontinence in Men, which we hope will also be beneficial to the growth of young surgeons and researchers.

Read More>>

Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney)

Better health awareness, access to healthcare and an improvement in diagnostic tests has led to a significant increase in the early detection and diagnosis of localised urological cancers. Expectant management or active surveillance (AS) is used in localised urological cancers and defined as the initial monitoring of tumour size and or grade, with delayed intervention only in tumours demonstrating clinical progression.

Read More>>

Management of Advanced Genitourinary Malignancies

There have been significant advances in the management of patients with advanced genitourinary malignancies in the last decade. These advances mostly affect prostate cancer, bladder cancer and renal cell carcinoma. For these patients, survival could be significantly improved by the introduction of new drugs including androgen-pathway targeting drugs for prostate cancer, immunotherapy and other targeted drugs (such as FGFR inhibitors and antibody drug conjugates) for urothelial carcinoma and immunotherapy combinations for renal cell carcinoma.

Read More>>

Current and Future Topics on Prostate Cancer

Reviews on novel hormonal agents and strategies for sequencing of various therapies seek to provide a good understanding of this dynamic area of research in prostate cancer. We have enjoyed editing this series and have ourselves learned a lot from the excellent articles. We hope you will likewise find them helpful in furthering your understanding of prostate cancer and for your clinical practice.

Read More>>

Urinary Biomarkers of Urothelial Malignancies

Given our increasingly aging society, the number of patients with malignant urogenital diseases (e.g., prostate cancer, urothelial cancer, renal cell carcinoma) is increasing. Meanwhile, overdiagnosis and overtreatment are also problems, especially given the morbidities of many of the treatments available such as radical prostatectomy or radical cystectomy.

Read More>>

Genetic Causes and Management of Male Infertility

This focused series of Translational Andrology and Urology explores our current understanding of the genetic causes and management of male infertility. Beginning with reviews of the basic genetic etiologies and relevant tests, this series then delves into well-known causes of male infertility including Y chromosome copy number variations, Y chromosome microdeletions, cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations, and hypogonadotropic hypogonadism. A novel review collates the available literature on nutrigenomics, detailing the interplay between diet, genetic makeup, and fecundity.

Read More>>

Controversies in Minimally Invasive Urologic Oncology

Over the past three decades, rapid development and application of minimally invasive surgical techniques has fundamentally altered the way urologists care for patients with urologic malignancies. The short-term gains of decreased blood loss, improved convalescence, and improved cosmesis have resulted in the rapid adoption of laparoscopy and robotics, and as a result the vast majority of prostate and kidney surgeries are now performed using the robotic platform in the absence of true long-term outcome improvement or cost benefits.

Read More>>

Update on Molecular Classification and Individualized Treatments of Genitourinary Tumors

This digital-based approach to histological diagnosis, also called DP, is a new approach in the morphologic analyses of glass slides either with tissue sections obtained from formalin-fixed paraffin embedded tissue (FFPE) or with frozen sections.

Read More>>